No near-term Reverse Stock Split required to meet Bid Price RuleHOUSTON, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced that it received a letter (the “Letter”) from Nasdaq on August 22, 2025, confirming its compliance with Nasdaq Listing Rule 5550(b). Specifically, the Letter confirms that the C ...

Core Points - Plus Therapeutics, Inc. reported stockholders' equity of $3 million as of June 30, 2025, satisfying Nasdaq Listing Rule 5550(b)(1) [1][4] - The company was previously notified on June 3, 2025, that it no longer met the Equity Rule as of March 31, 2025, leading to a delist determination [2] - Following a hearing on July 15, 2025, the Nasdaq Hearings Panel granted an extension for the company to demonstrate compliance with the Equity Rule [3] Company Overview - Plus Therapeutics is a clinical-stage pharmaceutical company based in Houston, Texas, focused on developing targeted radiotherapeutics for central nervous system cancers [5] - The company utilizes image-guided local beta radiation and targeted drug delivery methods, with lead programs addressing leptomeningeal metastases and recurrent glioblastoma [5] - Plus Therapeutics has established a supply chain through strategic partnerships to support the development, manufacturing, and potential commercialization of its products [5]

Core Insights - Plus Therapeutics, Inc. is set to provide a business update on June 26, 2025, before the market opens, followed by a conference call and webcast at 9:00 a.m. ET [1] Company Overview - Plus Therapeutics is a clinical-stage pharmaceutical company based in Houston, Texas, focused on developing targeted radiotherapeutics for challenging central nervous system cancers [4] - The company aims to enhance clinical outcomes through a combination of image-guided local beta radiation and targeted drug delivery approaches [4] - Plus Therapeutics has a pipeline of product candidates, with lead programs targeting leptomeningeal metastases and recurrent glioblastoma [4] - The company has established a supply chain through strategic partnerships to support the development, manufacturing, and potential commercialization of its products [4]

Core Insights - Plus Therapeutics has announced a comprehensive restructuring of its previous $15 million equity financing, which eliminates the potential issuance of up to 1.5 billion shares of common stock, aiming to enhance shareholder value and simplify its equity capital structure [1][6]. Company Overview - Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company based in Houston, Texas, focused on developing targeted radiotherapeutics for challenging central nervous system cancers, with a pipeline that includes programs for leptomeningeal metastases and recurrent glioblastoma [4]. Restructuring Details - The restructuring involves the cancellation of approximately 25 million shares of common stock or pre-funded warrants, which will further reduce stockholder dilution [6]. - The company has filed a request with the SEC to withdraw the resale registration statement related to the March 2025 equity financing [3]. - Future financing provisions state that 90% of proceeds from any capital raised after July 1, 2025, will be used to repay holders of 22,727,270 shares of common stock at 115% of the original price paid, based on an effective initial price of $0.66 per share [6].